Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

Novo Nordisk’s haemophilia A therapy Mim8 stopped bleeding completely in 74.3% of children in a Phase III trial. The ...

NHS England has agreed to reimburse Roche’s Hemlibra (emicizumab) in a new group of patients with haemophilia A, widening access to the potentially life-saving drug. Following the commissioning ...

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

That was before the spectacular success of Hemlibra, a bispecific antibody-based drug that mimics the function of Factor VIII by bridging clotting factors on either side of it in the clotting pathway.

Hemlibra was found to ease pain and improve quality of life for hemophilia A patients, even those with long-term joint damage, per a study.

The top four growth drivers — Vabysmo, Phesgo, Ocrevus and Hemlibra — achieved total sales of CHF 16.9 billion, reflecting an increase of CHF 3.3 billion from that recorded in 2023.

RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.